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background:  Factor Xa inhibitors (FXai) are an option for stroke prevention in patients with atrial fibrillation (SPAF). Reduced doses 
of FXai are recommended for moderate renal dysfunction or increased bleeding risk. In ROCKET-AF, 10.3% of patients met criteria for 
reduced-dose rivaroxaban, and in ARISTOTLE and AVERROES, 4.6% and 6.5% of patients met criteria for reduced-dose apixaban. 
IMS sales data in Canada reveal that 29-34% of patients treated with FXai for SPAF receive reduced-dose therapy. The proportion of AF 
patients in clinical practice truly meeting criteria for reduced-dose FXai is unknown.
Methods:  The SPRINT-AF Registry was a cross-sectional analysis of 936 consecutive AF patients from 109 Canadian practices between 
Dec 2012 and July 2013. Using clinical trial criteria, we estimated the prevalence of patients in SPRINT-AF who would be eligible for 
reduced-dose FXai therapy. Patients with a CHADS2 score of 0 were excluded from the analysis.
results:  Median age was 76 years, with 62% being male. Rates of hypertension (74%), dyslipidemia (61%), diabetes (30%), history of 
smoking (45%), coronary artery disease (25%), stroke (16%) and heart failure (19%) were consistent with contemporary AF studies. Two-
thirds (65%) had a CHADS2 score >2 and 87% had a CHADSVaSc score >2. Based on dosing criteria in ROCKET-AF (15 mg daily if the 
creatinine clearance was 30-49 mL/min/1.73 m²) and in ARISTOTLE / AVERROES (2.5 mg bid if a patient had any 2 of: age ≥ 80, weight ≤ 
60kg, or serum creatinine ≥1.5 mg/dl), 11.8% and 8.7% of the SPRINT-AF cohort would be eligible for reduced FXai dosing, respectively.
Conclusion:  SPRINT-AF demonstrates that a small proportion of AF patients meet the criteria for reduced-dose FXai therapy, verifying 
findings from large clinical trials. Given that the actual use of reduced-dose FXai based upon prescription data is substantially higher, it is 
possible that many patients are being under-dosed or inadequately anticoagulated. These observations highlight the importance of using 
full doses in the vast majority of patients requiring FXai therapy. Further research is needed to account for the high proportion of reduced-
dose FXai prescriptions in Canadian practice.
